A placebo-controlled, first-in-human phase I study of the anti-ADAMTS-5 nanobody M-6495 Nov. 19, 2019
3SBio and Verseau select VTX-0811 as first licensed program under immuno-oncology partnership Nov. 19, 2019
First placebo-controlled trial in renal scleroderma shows positive results for zibotentan Nov. 19, 2019
RSS